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Cytokine Concentration
IL-2 4000-8000pg/mL
IFNg 1000-3800pg/mL
IL-1b 300-1400pg/mL
TNFa 1000-4300pg/mL
Also contains measurable amounts  of: 
IL-6, IL-8, GM-CSF,G-CSF
Conclusions and Future Directions
PatientID Age
Estrogen  
Receptor
(%)
Progestero
ne  
Receptor%
HER2
status Grade Ki67% Tumor size
LymphNode  
involvement
IRXB-001 78 100% 100% Negative 2 11% 1.9cm Yes
IRXB-002 58 96.30% 90.10% Negative 2 19% 2.4cm Yes
IRXB-003 40 98% 100% Negative 2 17% 3.0cm Yes
IRXB-004 64 0% 0% Positive 3 75% 4.2cm Yes
IRXB-005 48 98% 92% Negative 1 7% 1.7cm Yes
IRXB-006 62 0% 0% Positive 3 73% 2.7cm Yes
IRXB-007 45 98 100 Negative 3 55% 3.7cm Yes
IRXB-008 54 100% 42% Negative 3 50% 2.1cm No
IRXB-009 56 100% 100% Negative 2 11% 0.7cm No
IRXB-010 46 100% 99% Negative 2 33% 1.8cm No
IRXB-011 52 69% 0% Positive 3 38% 1.5cm Yes
IRXB-012 52 98% 100% Positive 3 12% 2.1cm No
IRXB-013 59 100% 7% Negative 3 87% 2.2cm No
IRXB-014 45 100% 100% Negative 1 N/A 2.2cm No
IRXB-015 61 100% 50% Negative 2 30% 1.9cm No
IRXB-016 66 0% 0% Negative 3 95% 1.0cm No
Figure 1: Regimen
Methods
Hypothesis
▪ IRX-2 is an injectable cytokine-based immunotherapy containing  
multiple cytokines derived  from ex vivo phytohemagglutinin-
stimulated donor lymphocytes
▪ Measurable constituents include: IFN gamma, IL-2, IL-1b, TNF⍺, IL-
6, IL-8,  GM-CSF, and G-CSF
▪ In preclinical models, IRX-2 activates T cells and natural killer cells,
and facilitates dendritic cell maturation
▪ In a phase I trial, neoadjuvant IRX-2 increased tumor-infiltrating  
lymphocytes (TILs) and shrank tumors in resectable head/neck  
squamous carcinoma (HNSCC)1
▪ Stromal TILs (sTILs) are associated with improved survival in early  
stage breast cancer (ESBC)
▪ Patients with early stage (I-III) breast cancer were enrolled pre- operatively
▪ Patients received low dose of cyclophosphamide (d1, 300 mg/m2) to
facilitate T-regulatory (T-reg) cell depletion2, followed by 10 days of subcutaneous peri-
areolar subcutaneous IRX-2 into the affected breast (1 mL × 2 at tumor axis and at 90°),
similar to sentinel lymph node mapping methodology;
▪ Subjects also received oral indomethacin, which may reverse
immunosuppression by modulating myeloid cells3
▪ Primary endpoint: feasibility
▪ Secondary endpoint: blinded assessment of sTILs by the 2015 San Antonio working
group criteria4
▪ Exploratory endpoints: comprehensive immune monitoring
To assess the feasibility of preoperative IRX-2, and its effect on TIL
recruitment and immune priming within breast and HNN tumors,
regional lymphatics, and peripheral blood.
1. Whiteside T, et al., Cancer Immunol Immunother. 
2012; 61:783-788.
2. Machiels J   et al., Cancer Res.
2001;61:3689-3697.
3. Thun M et al., J  Natl Cancer Inst.
2002;94:252-66.
4. Salgado R et al., Ann Oncol.
2015;26:259-271.
• IRX-2 was well tolerated, with no treatment-related grade 3 or 4
toxicities or surgical delays;
• In breast cancer, IRX-2 enhances TIL recruitment and PD-L1 expression 
(by mRNA and mIHC);
• Peripheral immune changes were associated with Cy administration but 
not IRX-2 injections;
• These preliminary findings will be further explored in a follow-up clinical
trial that compares anti-PD- 1 +/- IRX-2 as induction therapy preceding
neoadjuvant chemotherapy in stage II-III triple negative breast cancer,
with a primary endpoint of pathologic complete response rate.
Portland, OR
No treatment-related grade 3/4 toxicities Figure 4: IRX-2 Increases immune checkpoint, leukocyte recruitment,  cytotoxic T-cells and leukocyte genes expression
Figure 5: Effects on peripheral T-cells
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ExploratoryEndpoints: RNAAnalysis
Exploratory Endpoints: Immune Monitoring
Fig.3 (a) Representative H&E,
PerkinElmer multispectral
immunohistochemistry (mIHC), and
PD-L1 immunofluorescence before and
after treatment; (b) mean PD-L1 per-
cell fluorescence before versus after
treatment, shown by breast cancer
subtype. Increases were observed in
12/15 patients (p=.07, Wilcoxon
matched-pairs rank test); (c) mRNA
transcript levels of PD-L1 by
Nanostring increased after IRX-2
treatment in 11/15 breast cancer
patients (p=.04, Wilcoxon matched-
pairs rank test).
Background
Toxicity GradeI/II,  
any attribution(%)
Grade I/II,  
attributedto  Cy(%)
Grade I/II,  
attributed  to Indo(%)
Grade I/II,  
attributedto  IRX-2(%)
Nausea 13 (81%) 3 (19%) 8(50%)
Bruising 8 (50%) 7 (44%)
Fatigue 9 (56%) 5 (31%)
Injection site reaction 8 (50%) 8 (50%)
Abdominal cramping/bloat 4(25%) 3(19%)
Increased ALT/AST/AlkP 4 (25%)
Anemia 4 (25%) 1 (6%) 1(6%)
Headache 5 (31%) 1 (6%)
Hypokalemia 4 (25%)
Anorexia 3 (19%)
Diarrhea 3 (19%) 1 (6%) 1(6%)
Flatulence 3 (19%) 2(13%)
Injection site pain 3 (19%) 3 (19%)
Vomiting 3 (19%) 2 (13%) 2(13%)
Figure 3: PD-L1 increases After IRX-2 Therapy (IHC and Nanostring)
Fig.4 (a-d) mRNA expression from
breast tissue, before versus after
treatment, were analyzed using
Nanostring pan-cancer immune panel.
Heat maps represent log2- transformed
fold-change in RNA expression levels.
Purple indicates increases in relative
expression, whereas beige indicates
decreases. Four RNA signatures were
established evaluating evaluating
markers for leukocyte recruitment,
cytotoxic T cells, leukocyte markers,
and checkpoints. Trends toward
increased T- cells recruitment
markers were observed with the
illustrated panels (e) % fold change
in Nanostring cell type frequencies,
representing an average of
functional genes associated with
each immune cell type. (f) Volcano
plot showing fold change in
individual genes (blue: p<.05; red
p<.01)
(f) Volcano plot showing fold
change in individual genes
(blue: p<.05; redp<.01)
Fig.5-II. Peripheral blood flow cytometry. Cy is
associated with sustained decreases in B-cell
populations, including total B-cells, transitioning B-
cells, naïve B-cells, and pre-switched B- cells, but
not plasma cells,n=16.
Fig.5-I Peripheral blood flow cytometry. (a-c) Cy
(cyclophosphamide) is associated with transient decreases
in absolute numbers of CD3, CD4 and CD8 T-cells, and
(d-f) transient depletion of T regs, proliferating T reg
fraction and their function (GzmB). n=16.
Fig.5-III. Peripheral blood flow cytometry. No changes
in % of dendritic cells (DC’s), DC activation markers
(CD40, CD86) or myeloid-derived suppressor cells
(MDSCs) were observed post IRX-2 therapy, n=16.
Table2. Treatment-related toxicities occurring in >15%of subjectsTable 1: Demographics and tumor characteristics of participants
Legend: Cy = cyclophosphamide; Sx = surgery; MDSC = myeloid-derived suppressor cells
Primary Endpoint: Feasibility
(Note:  transient treatment-unrelated grade III syncope was observed in one  subject with prior history ofvasovagal syncope)
SecondaryEndpoints
Figure 2: sTIL increases After IRX-2Therapy
Fig.2 (a) Representative H&E
demonstrating an increase in TILs in
an ESBC patient. (b) In ESBC,
treatment was associated with a
mean relative increase in TILs of
116% by Salgado scoring (range –36%
to +1275%, p* = 0.02). (c) In HNSCC,
treatment was associated with a
mean relative increase in TILs of
58% (range -57 to +452%,
p*=0.01). (a-c) TILs were scored by
two independent pathologists for
ESBC and HNSCC trial. ESBC; n=16;
HNSCC;n=36.
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